ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Want to see ZVSA full AI Analyst Report?
ZVSA Stock Chart & Stats
$0.13
-$0.05(-3.87%)
At close: 4:00 PM EST
$0.13
-$0.05(-3.87%)
Day’s Range― - ―
52-Week Range$0.11 - $1.67
Previous CloseN/A
Volume38.43K
Average Volume (3M)51.59K
Market Cap
$1.38M
Enterprise Value$899.00M
Total Cash (Recent Filing)$302.66M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.32
Shares Outstanding8,095,921
10 Day Avg. Volume65,792
30 Day Avg. Volume51,592
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-156.26
Enterprise Value/Market Cap653.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-36.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-65.8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Pipeline In Renal And Inflammatory DiseasesZyVersa runs a focused clinical-stage strategy with two distinct candidates (VAR 200 and IC 100) addressing renal and inflammasome-driven inflammatory indications. A concentrated, indication-driven pipeline can sustain strategic clarity, partnership interest, and targeted clinical progress over the next several months.
Lean Organizational Structure With Low Fixed OverheadA tiny headcount implies low fixed overhead and operational lean-ness, which can meaningfully extend runway per dollar of capital and allow management to allocate scarce resources toward core clinical activities, improving capital efficiency over a multi-month horizon.
Secured Convertible Note Financing To Provide Near-term Working CapitalThe $1M convertible note financing, with 10% interest and 12-month maturity, delivers committed near-term cash to fund operations and trials. Access to external financing demonstrates the company's ability to secure capital to sustain development activities in the coming months.
Bears Say
Material Balance Sheet Deterioration And Large Equity DeficitDeeply negative equity and rapidly rising debt relative to assets indicate severe capital structure stress, limiting financial flexibility. This elevates refinancing, covenant, and counterparty risk and weakens the company's ability to fund trials without dilutive or onerous financing terms over coming months.
Severe, Worsening Cash Burn And Negative Free Cash FlowPersistently negative operating and free cash flows that worsened in 2025 show accelerating cash consumption. Continued burn requires recurring financing to sustain operations, constraining strategic options and increasing dilution or debt risk in the medium term.
Pre-revenue Profile With Persistent, Large Net LossesZero revenue and escalating net losses confirm dependency on external capital rather than operating cash generation. Without commercialization or partnering milestones, the firm’s ability to self-fund development is limited, maintaining long-term execution and funding risk.
ZyVersa Therapeutics News
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $1.67 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
ZyVersa Therapeutics’s market cap is $1.38M.
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 79 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.22.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Overvalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 8,095,921 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.556%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Currently, no hedge funds are holding shares in ZVSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
6.64%
Insiders
<0.01% Other Institutional Investors
93.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---